ClinicalTrials.gg
CompletedNCT00060905Updated Aug 4, 2006

An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder

A Phase 3 interventional study of Divalproex Sodium (Depakote ER) in Bipolar Disorder, sponsored by Abbott. Completed at 18 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2006-08-04.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
370
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing Valproic Acid in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Valproic Acid · Bipolar Disorder.

Enrollment
4th of 41
370 · median 58
Started
2003
with 6 others
Phase 3
11 of 41
none open now
Registered
3rd of 41
by date
Lead sponsor
2 of 41
Abbott

Among the 41 studies testing Valproic Acid in Bipolar Disorder, this one is the 4th largest by enrollment, is one of 7 that started in 2003, is one of 11 in phase 3, and was the 3rd registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 41 studies testing Valproic Acid in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About Valproic Acid

Valproic Acid: first FDA approval 1978 (DEPAKENE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 41 studies testing Valproic Acid in Bipolar Disorder as a file.
02

Study summary

The purpose of this study is to determine the safety and effectiveness of Depakote ER compared to placebo in the treatment of bipolar disorder, manic or mixed type in adults.

03

Conditions studied

  • Bipolar Disorder

Keywords

  • Bipolar Disorder (manic or mixed type)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current primary diagnosis of bipolar I disorder, mania or mixed type
  • Acute exacerbation of mania associated with bipolar disorder as defined by Mania Rating Scale score >= 18
  • Hospitalized no more than 7 days at time of Screening or in process of being admitted
  • History of at least one prior manic or mixed episode within past 3 years, exclusive of the current episode. Prior manic or mixed episode must be separated from current episode by at least 2 months of sustained improvement

Exclusion criteria

EXCLUSION CRITERIA

  • History of schizophrenia or schizoaffective disorder
  • Axis I (e.g., anxiety disorder), or Axis II (e.g., personality disorder) that would interfere with compliance or confound interpretation of study results
  • Current manic or mixed episode is drug-induced or secondary to a medical disorder (e.g., AIDS, )
  • Current manic or mixed episode is believed to be caused by antidepressant use (i.e., antidepressant-induced mania)
  • Had first manic episode after age 60
  • Has ever taken clozapine
  • Has received depot neuroleptic medication within one inter-injection interval of first dose of study drug
  • Urine toxicology screen is positive for phencyclidine (PCP), opiates, cocaine or amphetamines
  • History of active alcohol or substance dependence within past 3 months.
  • History of failed treatment on adequate valproate therapy for bipolar disorder
  • Has taken Depakote (DR or ER) regularly over the last 30 days
  • Has serious violent, homicidal, or suicidal ideation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
370 participants
06

What researchers measure

Primary outcomes

  1. Change from baseline to the final evaluation for the MRS from the SADS-C for the intent-to-treat dataset.

Secondary outcomes

  1. Change from baseline to the final evaluation for the Manic Syndrome Scale (MSS), Behavior and Ideation Scale (BIS),

  2. BPRS (and published subscales), Global Assessment Scale (GAS), the Nursing Observation Scale for Inpatient Evaluation (NOSIE), and Burden Questionnaire, as well as the percentage of subjects with at least 50% improvement on the MRS.

07

Study locations

18 sites
  • Comprehensive Neuroscience of SCA
    Cerritos, California 90703, United States
  • AVI Clinical Research
    Torrance, California 90505, United States
  • Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Mark Lerman, MD
    Hoffman Estates, Illinois 60194, United States
  • University of Louisville Bipolar Research Program
    Louisville, Kentucky 40202, United States
  • Brentwood Research Inst.
    Shreveport, Louisiana 71101, United States
  • Centers for Behavioral Health, LLC
    Rockville, Maryland 20850, United States
  • McLean Hospital
    Belmont, Massachusetts 02478, United States
  • Pioneer Research
    Baltimore, Michigan 48047, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Steven A. Glass, MD
    Clementon, New Jersey 08021, United States
  • The Holliswood Hospital
    Holliswood, New York 11423, United States
  • NYU School of Medicine - Bellevue
    New York, New York 10016, United States
  • MetroHealth Medical Center
    Cleveland, Ohio 44109, United States
  • UT Mental Sciences Institute
    Houston, Texas 77030, United States
  • San Antonio State Hospital
    San Antonio, Texas 78223, United States
  • CNS of Northern Virginia
    Falls Church, Virginia 22041, United States
  • VAMC
    MIlwaukee, Wisconsin 53295, United States
08

References and documents

Publications

  • Hirschfeld RM, Bowden CL, Vigna NV, Wozniak P, Collins M. A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania. J Clin Psychiatry. 2010 Apr;71(4):426-32. doi: 10.4088/JCP.08m04960yel. Epub 2010 Mar 9. PubMed 20361904 ↗
  • Bowden CL, Swann AC, Calabrese JR, Rubenfaer LM, Wozniak PJ, Collins MA, Abi-Saab W, Saltarelli M; Depakote ER Mania Study Group. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry. 2006 Oct;67(10):1501-10. doi: 10.4088/jcp.v67n1003. PubMed 17107240 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 4, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00060905
Lead sponsor
Abbott
First posted
May 16, 2003
Start date
Jan 2003
Last update
Aug 4, 2006

Study contacts

Global Medical Information - Abbott
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valproic Acid

Start the discussion